BAUSCH & LOMB ENVISIONS "CONSIDERABLE" COST SAVINGS FROM STORZ, CHIRON VISION CONSOLIDATION; B&L HIGHLIGHTS STORZ' "LOW-COST" IOL MANUFACTURING
This article was originally published in The Gray Sheet
Executive SummaryBausch & Lomb expects to see "considerable" cost savings by 1999 from the consolidation of Storz Instruments and Chiron Vision, primarily through combination of the two firms' intraocular lens businesses. B&L announced definitive agreements to acquire both ophthalmic products companies were announced the week of Oct. 20.
You may also be interested in...
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.
Shares in Iovance Biotherapeutics have soared this week amid reports the US clinical-stage biotechnology company is in active M&A talks.